Denali Therapeutics Stock Forecast, Price & News

+1.89 (+2.73 %)
(As of 06/23/2021 05:14 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume444,372 shs
Average Volume582,032 shs
Market Capitalization$8.61 billion
P/E Ratio308.84
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DNLI News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Denali Therapeutics logo

About Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.32 out of 5 stars

Medical Sector

839th out of 2,105 stocks

Biological Products, Except Diagnostic Industry

124th out of 198 stocks

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

Is Denali Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Denali Therapeutics stock.
View analyst ratings for Denali Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Denali Therapeutics?

Wall Street analysts have given Denali Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Denali Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Denali Therapeutics

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings data on Sunday, May, 2nd. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.24. The business earned $7.90 million during the quarter, compared to the consensus estimate of $31.62 million. Denali Therapeutics had a trailing twelve-month return on equity of 6.36% and a net margin of 17.02%. The business's quarterly revenue was up 119.4% on a year-over-year basis.
View Denali Therapeutics' earnings history

How has Denali Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Denali Therapeutics' stock was trading at $16.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DNLI stock has increased by 320.8% and is now trading at $71.03.
View which stocks have been most impacted by COVID-19

What price target have analysts set for DNLI?

8 brokerages have issued 12-month price objectives for Denali Therapeutics' stock. Their forecasts range from $50.00 to $105.00. On average, they anticipate Denali Therapeutics' stock price to reach $80.86 in the next twelve months. This suggests a possible upside of 13.8% from the stock's current price.
View analysts' price targets for Denali Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the following people:
  • Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO & Director (Age 45, Pay $1.25M)
  • Dr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 48, Pay $820.32k)
  • Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 61, Pay $59.5k)
  • Mr. Steve Edward Krognes, CFO & Treasurer (Age 53, Pay $882.96k)
  • Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 48, Pay $835.08k)
  • Mr. Tyler M. Nielsen, VP of Corp. Fin. (Age 43)
  • Dr. Dana Andersen, Chief Technical and Manufacturing Officer
  • Mr. Joe Lewcock, Chief Scientific Officer
  • Dr. Laura Hansen, VP of Investor Relations
  • Mr. Chris Walsh, Associate Gen. Counsel

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics CEO Ryan Watts on Ryan Watts has an approval rating of 100% among Denali Therapeutics' employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Denali Therapeutics' key competitors?

What other stocks do shareholders of Denali Therapeutics own?

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (10.72%), BlackRock Inc. (5.42%), Price T Rowe Associates Inc. MD (5.00%), Gilder Gagnon Howe & Co. LLC (2.48%), Credit Suisse AG (1.62%) and Geode Capital Management LLC (1.03%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Steve E Krognes and Vicki L Sato.
View institutional ownership trends for Denali Therapeutics

Which major investors are selling Denali Therapeutics stock?

DNLI stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, JPMorgan Chase & Co., Gilder Gagnon Howe & Co. LLC, Bank of New York Mellon Corp, UBS Asset Management Americas Inc., Federated Hermes Inc., Goldman Sachs Group Inc., and Arrowstreet Capital Limited Partnership. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Steve E Krognes, and Vicki L Sato.
View insider buying and selling activity for Denali Therapeutics
or view top insider-selling stocks.

Which major investors are buying Denali Therapeutics stock?

DNLI stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Credit Suisse AG, Renaissance Technologies LLC, Morgan Stanley, BlackRock Inc., Bamco Inc. NY, Artisan Partners Limited Partnership, and Principal Financial Group Inc..
View insider buying and selling activity for Denali Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $71.03.

How much money does Denali Therapeutics make?

Denali Therapeutics has a market capitalization of $8.61 billion and generates $335.66 million in revenue each year. The company earns $71.14 million in net income (profit) each year or $0.63 on an earnings per share basis.

How many employees does Denali Therapeutics have?

Denali Therapeutics employs 311 workers across the globe.

What is Denali Therapeutics' official website?

The official website for Denali Therapeutics is

Where are Denali Therapeutics' headquarters?

Denali Therapeutics is headquartered at 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.